Francisco Trust Under Agreemen Sells 20,000 Shares of Dyadic International (NASDAQ:DYAI) Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $1.92, for a total transaction of $38,400.00. Following the completion of the sale, the insider directly owned 3,390,664 shares of the company’s stock, valued at $6,510,074.88. The trade was a 0.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Dyadic International Price Performance

NASDAQ DYAI opened at $1.06 on Wednesday. The company has a market cap of $38.63 million, a PE ratio of -4.61 and a beta of 1.15. The firm’s 50 day moving average price is $0.78 and its 200-day moving average price is $0.83. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. Dyadic International Inc. has a 52-week low of $0.65 and a 52-week high of $1.35.

Dyadic International (NASDAQ:DYAI) last posted its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The company had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. Sell-side analysts forecast that Dyadic International Inc. will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Dyadic International

Several institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its holdings in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the last quarter. Marathon Capital Management purchased a new stake in shares of Dyadic International during the 3rd quarter valued at $41,000. Geode Capital Management LLC boosted its position in shares of Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Dyadic International in the 3rd quarter worth $190,000. Finally, Apis Capital Advisors LLC purchased a new position in Dyadic International during the 3rd quarter worth $1,817,000. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Key Dyadic International News

Here are the key news stories impacting Dyadic International this week:

• Positive Sentiment: Dyadic said global collaborations are continuing to validate its C1 platform and expand commercial potential, including work tied to Ebola preparedness, which may improve the long-term outlook for its technology. Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
• Neutral Sentiment: Recent quarterly results were mixed: revenue came in above expectations, but EPS missed estimates, keeping attention on whether Dyadic can convert its technology into sustained profitability.
• Negative Sentiment: Major shareholder Francisco Trust Under Agreement disclosed multiple recent stock sales, which may pressure sentiment because insider selling can raise concerns about near-term confidence in the shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.